EQL Pharma AB (publ) (STO:EQL)

EQL Pharma AB Balance Sheet

Financials in millions SEK. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	61.1	86.76	82.4	20.47	44.43	41.2
Cash & Short-Term Investments	61.1	86.76	82.4	20.47	44.43	41.2
Cash Growth	8.90%	5.29%	302.58%	-53.93%	7.83%	55.01%
Accounts Receivable	82.15	108.71	130.72	60.77	51.7	34.1
Other Receivables	22.15	3.39	1.4	5.21	0.96	0.71
Receivables	104.31	112.11	132.12	65.98	52.66	34.81
Inventory	198.86	200.53	179.03	105.63	65.37	41.67
Prepaid Expenses	-	4.24	6.25	4.75	4.2	2.24
Other Current Assets	-	0.24	0.45	0.94	0.57	3.53
Total Current Assets	364.26	403.87	400.25	197.77	167.23	123.45
Property, Plant & Equipment	5.6	5.9	6.33	2.67	3.15	4.19
Long-Term Investments	0	0	0	0	0	0
Other Intangible Assets	449.66	375.2	364.67	149.08	102.54	98.41
Long-Term Deferred Charges	-	65.91	37.58	24.24	12.78	11.83
Other Long-Term Assets	0	-	-0	-	-	-
Total Assets	819.52	850.89	808.82	373.76	285.7	237.89

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	60.77	70.26	90.94	49.83	29.61	15.98
Accrued Expenses	-	15.78	10.29	6.65	17.87	16.28
Short-Term Debt	114.08	107.54	107.41	102.22	63.7	59.32
Current Portion of Long-Term Debt	-	3.73	4.11	-	-	5.4
Current Portion of Leases	-	2.9	2.75	1.4	1.21	-
Current Income Taxes Payable	-	5.95	3.99	-	0.14	-
Other Current Liabilities	24.67	4.08	1.53	1.43	4.66	1.64
Total Current Liabilities	199.52	210.23	221.02	162.05	117.19	98.76
Long-Term Debt	345.62	342.49	338.39	15.45	-	7.2
Long-Term Leases	-	2.69	3.05	1.02	1.71	4.18
Long-Term Deferred Tax Liabilities	24.08	28.43	25.34	17.51	12.05	4.12
Other Long-Term Liabilities	-	0	0	-	0	-
Total Liabilities	569.22	583.83	587.79	196.03	130.94	114.26

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	250.31	1.33	1.31	1.31	1.31	1.31
Additional Paid-In Capital	-	101.1	67.64	67.45	67.18	66.99
Retained Earnings	-	164.63	152.08	108.97	86.26	55.33
Comprehensive Income & Other	-	-	-	-0	-	-
Shareholders' Equity	250.31	267.06	221.03	177.73	154.75	123.63
Total Liabilities & Equity	819.52	850.89	808.82	373.76	285.7	237.89

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	459.69	459.34	455.71	120.09	66.62	76.1
Net Cash (Debt)	-398.6	-372.58	-373.31	-99.63	-22.19	-34.9
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-13.45	-12.35	-12.49	-3.34	-0.75	-1.20
Filing Date Shares Outstanding	29.53	29.53	29.06	29.06	29.06	29.06
Total Common Shares Outstanding	29.53	29.53	29.06	29.06	29.06	29.06
Working Capital	164.74	193.64	179.23	35.72	50.04	24.7
Book Value Per Share	8.48	9.04	7.61	6.12	5.32	4.25
Tangible Book Value	-199.36	-108.15	-143.63	28.65	52.21	25.21
Tangible Book Value Per Share	-6.75	-3.66	-4.94	0.99	1.80	0.87
Machinery	-	5.66	4.47	3.17	0.99	2.14

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 13, 2026

Data Sources Report a data error